Nausea , vomiting , and diarrhea were more common in the apremilast group ( with 22 , 9 , and 12 incidents , respectively , among 55 patients ) than in the placebo group ( with 10 , 1 , and 2 incidents , respectively , among 56 patients ) , findings that were similar to those in previous studies of apremilast .